Helena Tayton-Martin
Fondateur chez ADAPTIMMUNE THERAPEUTICS PLC
Fortune : 318 060 $ au 30/04/2024
Profil
Dr. Helena K.
Tayton-Martin is a Chief Business & Strategy Officer at Adaptimmune Therapeutics Plc, a COO, Director & Chief Business Officer at Adaptimmune Ltd.
and a President & Secretary at Adaptimmune LLC.
She is on the Board of Directors at Adaptimmune Ltd.
Dr. Tayton-Martin was previously employed as an Independent Director by Trillium Therapeutics ULC, a Chief Operating Officer by Avidex Ltd., and a Principal by Medigene, Inc. She received her MBA from London Business School and a doctorate degree from the University of Bristol.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
01/04/2024 | 1 800 000 ( 0,32% ) | 318 060 $ | 30/04/2024 |
Postes actifs de Helena Tayton-Martin
Sociétés | Poste | Début |
---|---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Fondateur | 01/01/2008 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Fondateur | 01/01/2008 |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | President | - |
Anciens postes connus de Helena Tayton-Martin
Sociétés | Poste | Fin |
---|---|---|
TRILLIUM THERAPEUTICS | Directeur/Membre du Conseil | 17/11/2021 |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Fondateur | 01/01/2017 |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Formation de Helena Tayton-Martin
London Business School | Masters Business Admin |
University of Bristol | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
Entreprise privées | 5 |
---|---|
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Health Services |